Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment selection after imatinib resistance in chronic myeloid leukemia.

Targeted oncology - 1 Jan 2009

Jabbour Elias, Cortes Jorge, Kantarjian Hagop

Abstract excerpt

Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood. The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase. The advent of imatinib, an inhibitor targeted specifically for BCR-ABL, represented a significant medical advance in CML therapy. However, patients with CML can exhibit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Dasatinib
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Practice Guidelines as Topic

Share to Stem Cell Transplantation

Share to Thiazoles

Source

Identifiers

PMID: 19343297
DOI: 10.1007/s11523-008-0100-y

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment selection after imatinib resistance in chronic myeloid leukemia.PMID 19343297Read ↗

Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Semantic proximity Read ↗

Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.Semantic proximity Read ↗

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.Semantic proximity Read ↗

Treatment of chronic myeloid leukemia when imatinib fails.Semantic proximity Read ↗

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?Semantic proximity Read ↗

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.Semantic proximity Read ↗

Practical considerations for monitoring patients with chronic myeloid leukemia.Semantic proximity Read ↗

Clinical resistance to imatinib: mechanisms and implications.Semantic proximity Read ↗

Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.Semantic proximity Read ↗

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.Semantic proximity Read ↗

Response definitions and European Leukemianet Management recommendations.Semantic proximity Read ↗

Pharmacogenetics and the treatment of chronic myeloid leukemia: how relevant clinically? An update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.